Technical Analysis for BIESF - Biotest Ag Pfd Shs N

Grade Last Price % Change Price Change
grade C 25.02 -0.16% -0.0400
BIESF closed down 0.16 percent on Friday, April 26, 2019, on 2.21 times normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A N/A
See historical BIESF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -0.16%
Hot IPO Pullback Bullish Swing Setup -0.16%
Narrow Range Bar Range Contraction -0.16%
New 52 Week Low Weakness -0.16%

Older signals for BIESF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in haematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin for the treatment of haemophilia A acute therapy and prophylaxis; Haemonine for haemophilia B acute therapy and prophylaxis; Cytotect for cytomegalovirus infections; and Fovepta for hepatitis B prophylaxis in newborns. The company's products also comprise Hepatect for prophylaxis of hepatitis B re-infection; Intratect for primary immune and secondary antibody deficiency syndromes and autoimmune diseases; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin for the treatment of blood volume depletion; Biseko to treat volume and serum protein depletion; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital and acquired fibrinogen deficiency; and Pentaglobin to treat bacterial infections. The company's products under development include Indatuximab Ravtansine (BT-062) for multiple myeloma and solid tumors; BT-063 for the treatment of systemic lupus erythematosus; BT-094 (Cytotect 70) to treat cytomegalovirus infections; Trimodulin for the community-acquired pneumonia; and Fibrinogen to treat fibrinogen deficiency. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. Biotest Aktiengesellschaft was founded in 1946 and is headquartered in Dreieich, Germany. As of January 19, 2018, Biotest Aktiengesellschaft operates as a subsidiary of Tiancheng International Investment Limited.
RTT Medical Specialties Branches Of Biology Autoimmune Diseases Solid Tumors Transplantation Blood Hepatitis Multiple Myeloma Bacterial Infections Coagulation System Haemophilia B Coagulation Haemophilia Systemic Lupus Erythematosus
Is BIESF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 0 bearish and 5 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 33.1
52 Week Low 25.02
Average Volume 1,133
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 0.0
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 25.0200
Resistance 3 (R3) 25.0200 25.0200 25.0200
Resistance 2 (R2) 25.0200 25.0200 25.0200 25.0200
Resistance 1 (R1) 25.0200 25.0200 25.0200 25.0200 25.0200
Pivot Point 25.0200 25.0200 25.0200 25.0200 25.0200
Support 1 (S1) 25.0200 25.0200 25.0200 25.0200 25.0200
Support 2 (S2) 25.0200 25.0200 25.0200 25.0200
Support 3 (S3) 25.0200 25.0200 25.0200
Support 4 (S4) 25.0200